secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001213900-23-067012
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q2 revenue falls 1% to $13.8M, GAAP EPS loss $(0.24), cuts 2023 outlook.
--------------------------------------------------------------------------------

- Revenue $13.8M, down 1% YoY; gross profit $7.8M, down 13%.
- GAAP net loss $(4.2)M ($(0.24)/share); non-GAAP net loss $(0.2)M ($(0.01)/share).
- Repurchased 526,999 shares at avg $14.27 for $7.5M in Q2.
- RWD.AI-enabled business saw 186% YoY growth in H1 2023.
- Full-year 2023 revenue guidance cut to mid-$50s to low-$60s million; gross margin 55-59%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390023067012/0001213900-23-067012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390023067012/ea183450-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-067012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer